The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.
May 1st 2024
A chemotherapy-free regimen of trastuzumab plus pertuzumab generated a strong 3-year iDFS rate in patients with HER2-positive early breast cancer.
eMonarcHER to Examine Abemaciclib Plus Adjuvant Endocrine Therapy in HER2+ Early Breast Cancer
The safety and efficacy of abemaciclib will be examined in patients with hormone receptor–positive, HER2-positive, node-positive, high-risk early breast cancer who have completed standard adjuvant HER2-targeted treatment as part of the phase 3 eMonarcHER trial.
Frontline Trastuzumab Deruxtecan Under Exploration With or Without Pertuzumab in HER2+ Breast Cancer
Fam-trastuzumab deruxtecan-nxki is under investigation with or without pertuzumab vs a standard-of-care regimen comprised of a taxane, trastuzumab, and pertuzumab in the frontline treatment of patients with HER2-positive metastatic breast cancer as part of the phase 3 DESTINY-Breast09 trial.
Trastuzumab Duocarmazine Shows Superiority Over Physician’s Choice for HER2+ Breast Cancer
The antibody-drug conjugate vic-trastuzumab duocarmazine was found to significantly improve progression-free survival over physician’s choice of treatment in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer, meeting the primary end point of the phase 3 TULIP trial.
Neoadjuvant Pyrotinib Quadruplet Significantly Improves pCR in HER2+ Breast Cancer
The combination of pyrotinib plus trastuzumab, docetaxel, and carboplatin (TCbH) significantly improved the total pathological complete response rate over TCbH alone in the neoadjuvant treatment of patients with HER2-positive breast cancer.
HER2+ Breast Cancer With Immune-Related Gene Signatures May Be Eligible for De-Escalation Approaches
Distinct gene signatures, with the exception of estrogen receptor signaling and BRCAness, are associated with pathologic complete response and invasive disease-free survival, in patients with HER2-positive breast cancer who received trastuzumab and pertuzumab alone or in combination with paclitaxel.
NICE Recommends Trastuzumab Deruxtecan in Advanced HER2+ Breast Cancer
The National Institute for Health and Care Excellence has published draft guidance that recommends fam-trastuzumab deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-positive breast cancer following 2 or more anti-HER2 therapies.
Future Is Wide Open for HER2+ Breast Cancer
April 12th 2021As longer-term follow-up data become available for several agents approved for HER2-positive metastatic breast cancer, investigators are looking closely at the characteristics of patients enrolled in those clinical trials to determine appropriate treatment strategies in the third-line setting and beyond.
Experts Take a Fresh Look at Strategies for Early-Stage HER2+ Breast Cancer
April 5th 2021Although trastuzumab-based regimens remain the standard treatment for patients with early-stage HER2-positive breast cancer, unanswered clinical questions surround the use of other agents in the neoadjuvant and adjuvant settings.
Meisel on Managing Toxicities With T-DM1 in HER2+ Breast Cancer
April 3rd 2021Data from the pivotal phase 3 KATHERINE has led to the addition of ado-trastuzumab emtansine to the HER2-positive breast cancer treatment arsenal, but the toxicities associated with the approach must be appropriately managed so that patients can continue to receive it.